[Form 4] CAMP4 Therapeutics Corporation Insider Trading Activity

Rhea-AI Filing Summary

Camp4 Therapeutics CEO and director Josh Mandel-Brehm reported acquiring 6,060 shares of the company's common stock on 09/11/2025 at a purchase price of $1.65 per share. The acquisition was made in a private placement governed by a Securities Purchase Agreement dated 09/09/2025 involving certain institutional investors and company insiders. Following the transaction, the reporting person beneficially owned 278,417 shares. The filing is a Form 4 disclosure of changes in beneficial ownership and does not include derivative transactions.

Positive

• Insider purchase disclosed: CEO and director acquired 6,060 shares at $1.65 per share.
• Clear compliance: Form 4 filed promptly showing transaction date 09/11/2025 and purchase agreement date 09/09/2025.

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: CEO purchased a modest stake in a private placement; disclosure aligns with Section 16 reporting requirements.

The Form 4 documents a direct purchase by the CEO and director under a Securities Purchase Agreement dated 09/09/2025. The size of the purchase, 6,060 shares at $1.65 each, and the resulting beneficial ownership of 278,417 shares are clearly disclosed. This is a routine insider purchase disclosed promptly on 09/11/2025 and demonstrates compliance with reporting obligations. No amendments or derivative positions are reported.

Securities Analyst

TL;DR: Transaction is informative but not material to valuation given disclosed share counts.

The report shows an insider acquisition executed in a private placement alongside institutional participants. The disclosed price per share and the small size of the transaction relative to total beneficial ownership suggest limited immediate market impact. The filing provides transparent detail on the transaction date, purchase price, and post-transaction ownership, useful for tracking insider activity but not indicating a material shift in control or capital structure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mandel-Brehm Josh

(Last) (First) (Middle)

C/O CAMP4 THERAPEUTICS CORPORATION

ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		P		6,060	A	$1.65(1)	278,417	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 11, 2025, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.

Remarks:

	/s/ Josh Mandel-Brehm	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CAMP CEO Josh Mandel-Brehm disclose on the Form 4?

He disclosed acquiring 6,060 shares of Camp4 common stock on 09/11/2025 at $1.65 per share in a private placement.

How many shares does Josh Mandel-Brehm beneficially own after the transaction?

The filing reports beneficial ownership of 278,417 shares following the reported purchase.

Was the acquisition part of a larger agreement?

Yes. The shares were acquired pursuant to a Securities Purchase Agreement dated 09/09/2025 involving institutional investors and certain directors, employees, and consultants.

Does the Form 4 report any derivative transactions or dispositions?

No. The filing lists a non-derivative acquisition and does not report any derivatives or dispositions.

When was the Form 4 signed and filed?

The filing bears the reporting person’s signature dated 09/11/2025.